Developer docs
API playgroundTry for free, no card

Search company profiles

INOFEA

Full company profile

uuid0007jnb

Namestring
INOFEA
Legal namestring
INOFEA AG
Websiteurl
inofea.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

INOFEA AG is a Swiss biotech company founded in 2014 as a spin-off from the University of Applied Sciences in Northwestern Switzerland (FHNW), headquartered in Muttenz (Basel area), Switzerland. The company has developed and patented an enzyme immobilization and shielding technology platform that grows a structured protective layer around enzymes, preventing denaturation and leaching while maintaining activity under harsh industrial process conditions including solvents, chaotropic agents, high temperatures, and wide pH ranges. The technology supports single enzymes as well as co-immobilized cocktails enabling cascade reactions, and enables implementation in continuous or semi-continuous manufacturing via flow-through or bed-packed reactors.

INOFEA's product portfolio spans ready-to-use immobilized enzymes (proteases, nucleases, polymerases), pipeline biologics-manufacturing enzymes (T7 RNA Polymerase, DNase I, S1 Nuclease), molecular biology enzymes, bioconjugation enzymes, and biocatalysis enzymes for small molecule API manufacturing. The company sells primarily to biologics manufacturers (mRNA vaccines/therapeutics, ADCs, downstream purification) and small molecule API manufacturers using biocatalytic processes, with secondary exposure to life science companies with specialized enzyme needs. Products are priced in CHF at approximately CHF 4,300–6,340 per unit via a direct e-commerce enzyme shop.

The company operates a three-pronged business model: (1) catalog enzyme product sales, (2) on-demand custom enzyme development services from feasibility through scale-up, and (3) technology licensing — demonstrated by a license to Perseo pharma. Commercial reach is augmented by a distribution partnership with Brenntag. INOFEA has ~11 team members, is privately held with angel-stage funding from Business Angels Switzerland and Venture Kick, and transitioned to a new CEO, Dr. Christoph Becker (ex-Novartis, Lonza, Siegfried), in August 2025.

Short descriptiontext

INOFEA AG is a Swiss biotech company that develops and sells immobilized, shielded enzymes for biologics manufacturing (mRNA, ADCs, downstream purification) and small molecule API biocatalysis, serving pharmaceutical and biotech customers via direct sales, custom development, and technology licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMuttenz, Switzerland
HQ citystring
Muttenz
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immobilized enzyme technology, biologics manufacturing enzymes, biocatalysis solutions, pharmaceutical enzyme products, custom enzyme development
Industry2 codes
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biocatalysis and Biopharmaceutical Manufacturing Enzymes
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Enzyme Product Sales
TypeOne Time License
Description

Sale of ready-to-use immobilized enzyme products including proteases, nucleases, polymerases, and biocatalysts. Products sold through website enzyme shop with publicly listed CHF prices. One-time purchase model per product.

inofea.com
2On-Demand Enzyme Development
TypeProfessional Services
Description

Custom enzyme development services working closely with clients from project scope analysis and feasibility study to development and production of formulated enzymes. Includes turnkey product manufacturing from small samples to large-scale production.

inofea.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing option allowing clients to integrate INOFEA's proprietary technology into their own manufacturing operations. Client benefits from proprietary know-how for greater efficiency and competitive edge.

inofea.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details8 tiers
1Proteinase K - Immobilized broad-spectrum serine protease
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 4,305.25 per unit. Used for protein digestion in nucleic acid extraction and sample preparation workflows.

inofea.com
2T7 RNA Polymerase - Immobilized RNA polymerase for mRNA production
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 6,339.14 per unit. Status: Production upon request. Minimum order: 20,000 units.

inofea.com
3Trypsin - Immobilized sequence-specific protease
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,429.97 per unit. Minimum order: 30 units.

inofea.com
4DNA/RNA nucleases - Immobilized nuclease preparation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,953.13 per unit.

inofea.com
5Microbial transglutaminase - Enzyme for protein crosslinking
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,775.00 per unit. Immobilization: Non-covalent & oriented. Surface modification: Negatively charged.

inofea.com
6Lipase B - Immobilized Candida antarctica lipase B
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,665.80 per unit. For esterification, transesterification, and stereoselective transformations.

inofea.com
7T4 DNA Ligase - Immobilized ligase for DNA joining
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,997.23 per unit. Packing: Spin-column.

inofea.com
8Protease Kit - Cocktail of 5 stabilized endo- and exo-peptidases
ModelUnit PricingBilling cadencePay-as-you-go
Notes

CHF 5,543.20 per kit. Contains all single proteases. Applications include biomarker identification, peptide mapping, protein characterization, and downstream purification of mAbs.

inofea.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

INOFEA develops and sells immobilized enzyme products (proteases, nucleases, polymerases, biocatalysts) using a proprietary shielding platform that prevents enzyme denaturation and leaching, enabling continuous bioprocessing for biologics manufacturing and small molecule API production. Beyond off-the-shelf enzymes, the company offers on-demand custom enzyme development services and licenses its core immobilization technology to pharmaceutical manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 20-fold increase in expression yield mentioned in ACROBiosystems Innovation Day presentations on AI-powered protein engineering
Product overview1 text field

INOFEA is a Swiss biotech company offering enzyme-based solutions for biologics manufacturing and small molecule API production. Their portfolio consists of ready-to-use enzyme products (Protease Kit, Carboxypeptidase Y, Leucine Aminopeptidase, Prolidase, Pronase, Proteinase K), pipeline products under development (T7 RNA Polymerase, DNase I, S1 Nuclease), molecular biology enzymes (Trypsin, T4 DNA Ligase, DNA/RNA Nucleases, PNGase F), bioconjugation enzymes (Microbial Transglutaminase), and biocatalysis enzymes (Amine Transaminase, Ketoreductase, Alpha-amylase, Urease, Glucose Isomerase, Lipase B, Lipoxygenase). All products feature their proprietary enzyme immobilization and shielding technology platform that enables enzyme stabilization, prevents leaching, and allows implementation in continuous or semicontinuous manufacturing processes. The company also provides On Demand Development services and Technology Licensing for custom enzyme solutions.

Product and service23 records
1Protease Kit
CategoryReady Product (Protease)
Description

Immobilized protease blend containing a cocktail of five stabilized endo- and exo-peptidases for complete protein hydrolysis, used in biomarker identification, peptide mapping, protein characterization, and downstream purification of monoclonal antibodies.

2Carboxypeptidase Y
CategoryReady Product (Protease)
Description

Stabilized serine protease exopeptidase with broad amino acid specificity that cleaves any terminal amino acid, including proline, from the carboxy-terminus of peptides, and is easily separated after reaction completion.

3Leucine Aminopeptidase
CategoryReady Product (Protease)
Description

Stabilized exopeptidase that catalyzes hydrolysis of amino acid residues from the amino-terminus of polypeptide chains, reacting most rapidly with leucine residues, and is easily separated after reaction completion.

4Prolidase
CategoryReady Product (Protease)
Description

Stabilized enzyme that catalyzes hydrolysis of the imide bond between an alpha-carboxyl group and proline or hydroxyproline, easily separated after reaction completion.

5Pronase
CategoryReady Product (Protease)
Description

Stabilized mixture of endo- and exoproteases with broad specificity that digests proteins to single amino acids, applicable for protein degradation during DNA and RNA isolation and easily collected from reactions to improve downstream purification.

6Proteinase K
CategoryReady Product (Protease)
Description

Stabilized broad-spectrum serine protease used for digestion of proteins including DNases and RNases, easily separated from reaction mixture to improve downstream purification, and implementable in continuous or semi-continuous manufacturing processes. Priced at CHF 4,305.25 per unit.

7T7 RNA Polymerase
CategoryPipeline Product (Polymerase)
Description

DNA-dependent RNA polymerase with specificity for double-stranded promoters, used in in vitro synthesis of mRNA, can be included in continuous or semi-continuous processes. Priced at CHF 6,339.14 per unit with a minimum order of 20,000 units, produced upon request.

8DNase I
CategoryPipeline Product (Nuclease)
Description

Enzyme that efficiently hydrolyzes single- and double-stranded DNA into mono- and oligo-deoxyribonucleotides, applied for removal of DNA template after in vitro transcription reactions, and implementable in continuous or semi-continuous processes.

9S1 Nuclease
CategoryPipeline Product (Nuclease)
Description

Hydrolyzes single-stranded RNA or DNA into 5-prime mononucleotides, applied in enzymatic degradation of DNA/RNA from proteins and other biologicals, and can be included in continuous or semi-continuous processes.

10Trypsin
CategoryMolecular Biology Enzyme
Description

Immobilized sequence-specific protease for protein digestion and peptide mapping workflows, with simple enzyme removal after digestion. Priced at CHF 5,429.97 per unit with a minimum order of 30 units.

11T4 DNA Ligase
CategoryMolecular Biology Enzyme
Description

Immobilized ligase for DNA joining and chemoenzymatic oligonucleotide workflows, enabling easier enzyme removal and potential repeated use. Priced at CHF 5,997.23 per unit and supplied in a spin-column format.

12DNA/RNA Nucleases
CategoryMolecular Biology Enzyme
Description

Immobilized nuclease preparation for controlled DNA and RNA digestion, nucleic acid clean-up, and analytical sample preparation. Priced at CHF 5,953.13 per unit.

13PNGase F
CategoryMolecular Biology Enzyme
Description

Immobilized amidase for enzymatic N-glycan release from glycoproteins in glycoprotein characterization and analytical sample preparation.

14Microbial Transglutaminase
CategoryBioconjugation Enzyme
Description

Immobilized enzyme for protein crosslinking and site-selective bioconjugation workflows, including antibody or peptide modification applications. Priced at CHF 5,775.00 per unit, with non-covalent and oriented immobilization on a negatively charged surface.

15Amine Transaminase
CategoryBiocatalysis Enzyme
Description

Immobilized amine transaminase for synthesis of chiral amines by amino-group transfer in biocatalytic pharmaceutical intermediate production.

16Ketoreductase
CategoryBiocatalysis Enzyme
Description

Immobilized ketoreductase for asymmetric ketone reduction to chiral alcohols in biocatalytic synthesis and pharmaceutical intermediate production.

17Alpha-amylase
CategoryBiocatalysis Enzyme
Description

Immobilized alpha-amylase for starch hydrolysis and carbohydrate processing, producing shorter oligosaccharides from alpha-1,4-glucans.

18Urease
CategoryBiocatalysis Enzyme
Description

Immobilized urease for urea hydrolysis to ammonia and carbon dioxide in analytical, environmental, and process applications.

19Glucose Isomerase
CategoryBiocatalysis Enzyme
Description

Immobilized glucose isomerase for glucose-to-fructose isomerization in carbohydrate processing and industrial biocatalysis.

20Lipase B
CategoryBiocatalysis Enzyme
Description

Immobilized Candida antarctica lipase B for esterification, transesterification, and stereoselective transformations in organic synthesis and biocatalysis. Priced at CHF 5,665.80 per unit.

21Lipoxygenase
CategoryBiocatalysis Enzyme
Description

Immobilized lipoxygenase for oxidation of polyunsaturated fatty acids, supporting lipid modification and analytical biocatalysis workflows.

22On Demand Development Services
CategoryService
Description

Custom enzyme development services covering project scope analysis, feasibility studies, and production of formulated enzymes tailored to specific client needs, from small sample manufacturing through large-scale production via trusted partners.

23Technology Licensing
CategoryService
Description

Licensing of INOFEA's proprietary enzyme immobilization and shielding technology, allowing clients to integrate the platform into their own manufacturing operations for greater efficiency and competitive advantage.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

INOFEA participated as a speaker at ACROBiosystems Innovation Day event in Zurich, Switzerland, alongside Wyss Zurich, University of Zurich, and Limula. Presented case studies on optimized cytokines and automated cell therapy manufacturing platforms.

2Perseo pharma
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

INOFEA has licensed its proprietary enzyme technology to Perseo pharma, allowing them to integrate the technology into their own manufacturing operations. This demonstrates the commercial viability of INOFEA's technology platform through technology licensing.

inofea.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

INOFEA is supported by Brenntag to efficiently increase awareness in the Pharmaceutical industry. Brenntag is a leading chemical and ingredients distributor, helping INOFEA expand market reach in the pharmaceutical sector.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

INOFEA was founded as a spin-off of FHNW. The technology was developed at FHNW as postdoc research. Dr. Rita Correro developed INOFEA's technology during her postdoc at FHNW.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based protein engineering company developing engineered enzymes and biocatalysts for pharmaceutical manufacturing. Highly comparable to INOFEA in serving pharma and biopharma customers with specialty enzymes, but at significantly greater scale and with a broader enzyme library.

TypeDirect peer
Description

Sweden-based company commercializing immobilized enzymes for sustainable chemical and pharmaceutical manufacturing. Directly comparable to INOFEA in technology platform (enzyme immobilization), target customer base (pharma/biotech manufacturers), and business model (products and licensing).

TypeEmerging player
Description

US-based manufacturer of resin-based products including chromatography and immobilization supports used in bioprocessing. Comparable to INOFEA in supplying bioprocess consumables and enabling enzyme immobilization, though Purolite focuses on the carrier resins rather than the finished immobilized enzymes.

4Amano Enzyme
TypeBroad incumbent
Description

Japanese enzyme manufacturer producing a wide range of industrial and specialty enzymes for food, pharmaceutical, and diagnostic applications. Broad incumbent with overlapping pharma and diagnostic enzyme portfolios serving similar B2B customers.

TypeDirect peer
Description

US-based enzyme supplier offering a broad catalog of enzymes for industrial and research applications. Comparable to INOFEA in selling specialty enzymes through an e-commerce channel and serving biotech customers, though at a smaller technical differentiation.

TypeEmerging player
Description

Global provider of proteins, antibodies, and reagents for biopharmaceutical R&D and manufacturing. Comparable to INOFEA in serving biologics manufacturers (mRNA, ADC, antibodies) with consumables and reagents, and an existing ecosystem partner through the Innovation Day relationship.

TypeDirect peer
Description

German biotechnology company developing and producing enzymes for industrial applications including pharmaceutical and food industries. Comparable to INOFEA in biocatalysis focus, B2B enzyme supply, and serving regulated manufacturing customers.

TypeBroad incumbent
Description

Danish global leader in enzyme production (formed by merger of Novozymes and Chr. Hansen). Broad incumbent in the enzyme space with overlapping biocatalysis offerings for pharma, food, and industrial markets; competes with INOFEA in pharma enzymes at much larger scale.

9Bisy
TypeDirect peer
Description

Austrian biocatalysis company developing enzymes for industrial and pharmaceutical manufacturing. Comparable to INOFEA in European footprint, enzyme technology focus, and serving manufacturing customers in pharma and chemicals.

TypeDirect peer
Description

UK-based company developing and producing biocatalysts for chemical and pharmaceutical industries. Directly comparable to INOFEA in offering specialty enzyme products and custom enzyme development services to pharma/biotech manufacturers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INOFEA

Biocatalysis and Biopharmaceutical Manufacturing Enzymesinofea.com

INOFEA AG is a Swiss biotech company that develops and sells immobilized, shielded enzymes for biologics manufacturing (mRNA, ADCs, downstream purification) and small molecule API biocatalysis, serving pharmaceutical and biotech customers via direct sales, custom development, and technology licensing.

What INOFEA does

INOFEA AG is a Swiss biotech company founded in 2014 as a spin-off from the University of Applied Sciences in Northwestern Switzerland (FHNW), headquartered in Muttenz (Basel area), Switzerland. The company has developed and patented an enzyme immobilization and shielding technology platform that grows a structured protective layer around enzymes, preventing denaturation and leaching while maintaining activity under harsh industrial process conditions including solvents, chaotropic agents, high temperatures, and wide pH ranges. The technology supports single enzymes as well as co-immobilized cocktails enabling cascade reactions, and enables implementation in continuous or semi-continuous manufacturing via flow-through or bed-packed reactors.

INOFEA's product portfolio spans ready-to-use immobilized enzymes (proteases, nucleases, polymerases), pipeline biologics-manufacturing enzymes (T7 RNA Polymerase, DNase I, S1 Nuclease), molecular biology enzymes, bioconjugation enzymes, and biocatalysis enzymes for small molecule API manufacturing. The company sells primarily to biologics manufacturers (mRNA vaccines/therapeutics, ADCs, downstream purification) and small molecule API manufacturers using biocatalytic processes, with secondary exposure to life science companies with specialized enzyme needs. Products are priced in CHF at approximately CHF 4,300–6,340 per unit via a direct e-commerce enzyme shop.

The company operates a three-pronged business model: (1) catalog enzyme product sales, (2) on-demand custom enzyme development services from feasibility through scale-up, and (3) technology licensing — demonstrated by a license to Perseo pharma. Commercial reach is augmented by a distribution partnership with Brenntag. INOFEA has ~11 team members, is privately held with angel-stage funding from Business Angels Switzerland and Venture Kick, and transitioned to a new CEO, Dr. Christoph Becker (ex-Novartis, Lonza, Siegfried), in August 2025.

INOFEA firmographics

Firmographics
Name
INOFEA
Legal name
INOFEA AG
Website
https://inofea.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
INOFEA AG is a Swiss biotech company that develops and sells immobilized, shielded enzymes for biologics manufacturing (mRNA, ADCs, downstream purification) and small molecule API biocatalysis, serving pharmaceutical and biotech customers via direct sales, custom development, and technology licensing.
Ownership category
akta.pro rank

INOFEA industry classification

Industry
Product category
Biocatalysis and Biopharmaceutical Manufacturing Enzymes
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services

Keywords

  • Immobilized enzyme technology
  • Biologics manufacturing enzymes
  • Biocatalysis solutions
  • Pharmaceutical enzyme products
  • Custom enzyme development

Where INOFEA is headquartered

Location

Headquarters

HQ city
Muttenz
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

INOFEA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Enzyme Product Sales: Sale of ready-to-use immobilized enzyme products including proteases, nucleases, polymerases, and biocatalysts. Products sold through website enzyme shop with publicly listed CHF prices. One-time purchase model per product.
  2. On-Demand Enzyme Development: Custom enzyme development services working closely with clients from project scope analysis and feasibility study to development and production of formulated enzymes. Includes turnkey product manufacturing from small samples to large-scale production.
  3. Technology Licensing: Licensing option allowing clients to integrate INOFEA's proprietary technology into their own manufacturing operations. Client benefits from proprietary know-how for greater efficiency and competitive edge.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProteinase K - Immobilized broad-spectrum serine protease
Unit PricingPay-as-you-goT7 RNA Polymerase - Immobilized RNA polymerase for mRNA production
Unit PricingPay-as-you-goTrypsin - Immobilized sequence-specific protease
Unit PricingPay-as-you-goDNA/RNA nucleases - Immobilized nuclease preparation
Unit PricingPay-as-you-goMicrobial transglutaminase - Enzyme for protein crosslinking
Unit PricingPay-as-you-goLipase B - Immobilized Candida antarctica lipase B
Unit PricingPay-as-you-goT4 DNA Ligase - Immobilized ligase for DNA joining
Unit PricingPay-as-you-goProtease Kit - Cocktail of 5 stabilized endo- and exo-peptidases

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

INOFEA product offering

Product offering

Core offering

INOFEA develops and sells immobilized enzyme products (proteases, nucleases, polymerases, biocatalysts) using a proprietary shielding platform that prevents enzyme denaturation and leaching, enabling continuous bioprocessing for biologics manufacturing and small molecule API production. Beyond off-the-shelf enzymes, the company offers on-demand custom enzyme development services and licenses its core immobilization technology to pharmaceutical manufacturers.

Product overview

INOFEA is a Swiss biotech company offering enzyme-based solutions for biologics manufacturing and small molecule API production. Their portfolio consists of ready-to-use enzyme products (Protease Kit, Carboxypeptidase Y, Leucine Aminopeptidase, Prolidase, Pronase, Proteinase K), pipeline products under development (T7 RNA Polymerase, DNase I, S1 Nuclease), molecular biology enzymes (Trypsin, T4 DNA Ligase, DNA/RNA Nucleases, PNGase F), bioconjugation enzymes (Microbial Transglutaminase), and biocatalysis enzymes (Amine Transaminase, Ketoreductase, Alpha-amylase, Urease, Glucose Isomerase, Lipase B, Lipoxygenase). All products feature their proprietary enzyme immobilization and shielding technology platform that enables enzyme stabilization, prevents leaching, and allows implementation in continuous or semicontinuous manufacturing processes. The company also provides On Demand Development services and Technology Licensing for custom enzyme solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Protease Kit Immobilized protease blend containing a cocktail of five stabilized endo- and exo-peptidases for complete protein hydrolysis, used in biomarker identification, peptide mapping, protein characterization, and downstream purification of monoclonal antibodies.
  • Carboxypeptidase Y Stabilized serine protease exopeptidase with broad amino acid specificity that cleaves any terminal amino acid, including proline, from the carboxy-terminus of peptides, and is easily separated after reaction completion.
  • Leucine Aminopeptidase Stabilized exopeptidase that catalyzes hydrolysis of amino acid residues from the amino-terminus of polypeptide chains, reacting most rapidly with leucine residues, and is easily separated after reaction completion.
  • Prolidase Stabilized enzyme that catalyzes hydrolysis of the imide bond between an alpha-carboxyl group and proline or hydroxyproline, easily separated after reaction completion.
  • Pronase Stabilized mixture of endo- and exoproteases with broad specificity that digests proteins to single amino acids, applicable for protein degradation during DNA and RNA isolation and easily collected from reactions to improve downstream purification.
  • Proteinase K Stabilized broad-spectrum serine protease used for digestion of proteins including DNases and RNases, easily separated from reaction mixture to improve downstream purification, and implementable in continuous or semi-continuous manufacturing processes. Priced at CHF 4,305.25 per unit.
  • T7 RNA Polymerase DNA-dependent RNA polymerase with specificity for double-stranded promoters, used in in vitro synthesis of mRNA, can be included in continuous or semi-continuous processes. Priced at CHF 6,339.14 per unit with a minimum order of 20,000 units, produced upon request.
  • DNase I Enzyme that efficiently hydrolyzes single- and double-stranded DNA into mono- and oligo-deoxyribonucleotides, applied for removal of DNA template after in vitro transcription reactions, and implementable in continuous or semi-continuous processes.
  • S1 Nuclease Hydrolyzes single-stranded RNA or DNA into 5-prime mononucleotides, applied in enzymatic degradation of DNA/RNA from proteins and other biologicals, and can be included in continuous or semi-continuous processes.
  • Trypsin Immobilized sequence-specific protease for protein digestion and peptide mapping workflows, with simple enzyme removal after digestion. Priced at CHF 5,429.97 per unit with a minimum order of 30 units.
  • T4 DNA Ligase Immobilized ligase for DNA joining and chemoenzymatic oligonucleotide workflows, enabling easier enzyme removal and potential repeated use. Priced at CHF 5,997.23 per unit and supplied in a spin-column format.
  • DNA/RNA Nucleases Immobilized nuclease preparation for controlled DNA and RNA digestion, nucleic acid clean-up, and analytical sample preparation. Priced at CHF 5,953.13 per unit.
  • PNGase F Immobilized amidase for enzymatic N-glycan release from glycoproteins in glycoprotein characterization and analytical sample preparation.
  • Microbial Transglutaminase Immobilized enzyme for protein crosslinking and site-selective bioconjugation workflows, including antibody or peptide modification applications. Priced at CHF 5,775.00 per unit, with non-covalent and oriented immobilization on a negatively charged surface.
  • Amine Transaminase Immobilized amine transaminase for synthesis of chiral amines by amino-group transfer in biocatalytic pharmaceutical intermediate production.
  • Ketoreductase Immobilized ketoreductase for asymmetric ketone reduction to chiral alcohols in biocatalytic synthesis and pharmaceutical intermediate production.
  • Alpha-amylase Immobilized alpha-amylase for starch hydrolysis and carbohydrate processing, producing shorter oligosaccharides from alpha-1,4-glucans.
  • Urease Immobilized urease for urea hydrolysis to ammonia and carbon dioxide in analytical, environmental, and process applications.
  • Glucose Isomerase Immobilized glucose isomerase for glucose-to-fructose isomerization in carbohydrate processing and industrial biocatalysis.
  • Lipase B Immobilized Candida antarctica lipase B for esterification, transesterification, and stereoselective transformations in organic synthesis and biocatalysis. Priced at CHF 5,665.80 per unit.
  • Lipoxygenase Immobilized lipoxygenase for oxidation of polyunsaturated fatty acids, supporting lipid modification and analytical biocatalysis workflows.
  • On Demand Development Services Custom enzyme development services covering project scope analysis, feasibility studies, and production of formulated enzymes tailored to specific client needs, from small sample manufacturing through large-scale production via trusted partners.
  • Technology Licensing Licensing of INOFEA's proprietary enzyme immobilization and shielding technology, allowing clients to integrate the platform into their own manufacturing operations for greater efficiency and competitive advantage.

Quantifiable outcome

  • 20-fold increase in expression yield mentioned in ACROBiosystems Innovation Day presentations on AI-powered protein engineering

Companies that use INOFEA

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

INOFEA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

INOFEA partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • ACROBiosystemsminorStrategic or Co-development Partner · 18 May 2026INOFEA participated as a speaker at ACROBiosystems Innovation Day event in Zurich, Switzerland, alongside Wyss Zurich, University of Zurich, and Limula. Presented case studies on optimized cytokines and automated cell therapy manufacturing platforms.
  • Perseo pharmacoreOEM/ Whitelabel/ Licensing PartnerINOFEA has licensed its proprietary enzyme technology to Perseo pharma, allowing them to integrate the technology into their own manufacturing operations. This demonstrates the commercial viability of INOFEA's technology platform through technology licensing.
  • BrenntagcoreChannel Partner/ Reseller/ DistributorINOFEA is supported by Brenntag to efficiently increase awareness in the Pharmaceutical industry. Brenntag is a leading chemical and ingredients distributor, helping INOFEA expand market reach in the pharmaceutical sector.
  • FHNW (University of Applied Sciences Northwestern Switzerland)coreStrategic or Co-development PartnerINOFEA was founded as a spin-off of FHNW. The technology was developed at FHNW as postdoc research. Dr. Rita Correro developed INOFEA's technology during her postdoc at FHNW.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

INOFEA competitors and assessment

Company assessment

Direct peers

  • Codexis: US-based protein engineering company developing engineered enzymes and biocatalysts for pharmaceutical manufacturing. Highly comparable to INOFEA in serving pharma and biopharma customers with specialty enzymes, but at significantly greater scale and with a broader enzyme library.
  • EnginZyme: Sweden-based company commercializing immobilized enzymes for sustainable chemical and pharmaceutical manufacturing. Directly comparable to INOFEA in technology platform (enzyme immobilization), target customer base (pharma/biotech manufacturers), and business model (products and licensing).
  • Creative Enzymes: US-based enzyme supplier offering a broad catalog of enzymes for industrial and research applications. Comparable to INOFEA in selling specialty enzymes through an e-commerce channel and serving biotech customers, though at a smaller technical differentiation.
  • c-LEcta: German biotechnology company developing and producing enzymes for industrial applications including pharmaceutical and food industries. Comparable to INOFEA in biocatalysis focus, B2B enzyme supply, and serving regulated manufacturing customers.
  • Bisy: Austrian biocatalysis company developing enzymes for industrial and pharmaceutical manufacturing. Comparable to INOFEA in European footprint, enzyme technology focus, and serving manufacturing customers in pharma and chemicals.
  • Prozomix: UK-based company developing and producing biocatalysts for chemical and pharmaceutical industries. Directly comparable to INOFEA in offering specialty enzyme products and custom enzyme development services to pharma/biotech manufacturers.

Emerging players

  • Purolite (Ecolab): US-based manufacturer of resin-based products including chromatography and immobilization supports used in bioprocessing. Comparable to INOFEA in supplying bioprocess consumables and enabling enzyme immobilization, though Purolite focuses on the carrier resins rather than the finished immobilized enzymes.
  • ACROBiosystems: Global provider of proteins, antibodies, and reagents for biopharmaceutical R&D and manufacturing. Comparable to INOFEA in serving biologics manufacturers (mRNA, ADC, antibodies) with consumables and reagents, and an existing ecosystem partner through the Innovation Day relationship.

Broad incumbents

  • Amano Enzyme: Japanese enzyme manufacturer producing a wide range of industrial and specialty enzymes for food, pharmaceutical, and diagnostic applications. Broad incumbent with overlapping pharma and diagnostic enzyme portfolios serving similar B2B customers.
  • Novonesis: Danish global leader in enzyme production (formed by merger of Novozymes and Chr. Hansen). Broad incumbent in the enzyme space with overlapping biocatalysis offerings for pharma, food, and industrial markets; competes with INOFEA in pharma enzymes at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

INOFEA social profiles

Digital presence

INOFEA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INOFEA leadership team

Management profile

Number of profiles

Profiles10 records

INOFEA funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INOFEA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INOFEA

What does INOFEA do?

INOFEA develops and sells immobilized enzyme products (proteases, nucleases, polymerases, biocatalysts) using a proprietary shielding platform that prevents enzyme denaturation and leaching, enabling continuous bioprocessing for biologics manufacturing and small molecule API production. Beyond off-the-shelf enzymes, the company offers on-demand custom enzyme development services and licenses its core immobilization technology to pharmaceutical manufacturers.

Is INOFEA a public or private company?

INOFEA is a private company. It is classified as venture growth investor backed and is currently operating.

When was INOFEA founded?

INOFEA was founded in 2014. It employs 11 to 50 people.

Where is INOFEA based?

INOFEA is headquartered in Muttenz, Switzerland, in the Europe region.

How does INOFEA make money?

Three revenue lines are on record. Enzyme Product Sales are the primary driver. The others are on-Demand Enzyme Development and technology Licensing.

Who are INOFEA's main competitors?

Direct peers on record are Codexis, EnginZyme, Creative Enzymes, c-LEcta, Bisy and Prozomix. Emerging players are Purolite (Ecolab) and ACROBiosystems. Broad incumbents are Amano Enzyme and Novonesis.

Does INOFEA have an API?

No public API is recorded for INOFEA.

What industry is INOFEA in?

INOFEA's product category is Biocatalysis and Biopharmaceutical Manufacturing Enzymes. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers), with a secondary code of HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals